Search Results | Blood | American Society of Hematology

1-20 of 74

2 3 4

Sort by

Sort Order Select

Journal Articles

Glutamine and CLL: ready for prime time?

Silvia Deaglio

Blood (2022) 140 (6): 528–529.

DOI: https://doi.org/10.1182/blood.2022016696

Published: 2022

Journal Articles

Anti-CD37 alpha-amanitin conjugated antibodies as potential therapeutic weapons for Richter's Syndrome

Tiziana Vaisitti, Nicoletta Vitale, Matilde Micillo, Lorenzo Brandimarte, Andrea Iannello, Mauro G Papotti, Ozren Jaksic, Gianluca Lopez, Arianna Di Napoli, Juan C. Cutrin, Christian Orlik, Michael Kulke, Andreas Pahl, Silvia Deaglio

Blood blood.2022016211.

DOI: https://doi.org/10.1182/blood.2022016211

Published: 2022

Includes: Supplemental data

Journal Articles

A new taxonomy for splenic marginal zone lymphoma

Silvia Deaglio, Tiziana Vaisitti

Blood (2022) 139 (5): 644–645.

DOI: https://doi.org/10.1182/blood.2021014198

Published: 2022

Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 3718.

DOI: https://doi.org/10.1182/blood-2021-150183

Published: 2021

Journal Articles

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Tiziana Vaisitti, Nicoletta Vitale, Andrea Iannello, Lorenzo Brandimarte, Matilde Micillo, Mauro Giulio Papotti, Arianna Di Napoli, Christian Orlik, Michael Kulke, Andreas Pahl, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 791.

DOI: https://doi.org/10.1182/blood-2021-150280

Published: 2021

Journal Articles

Evidence of a Synergistic Cross-Talk between the B Cell Receptor (BCR) and Nicotinamide Phosphoribosyl Transferase (NAMPT) in Richter's Syndrome Patient-Derived Xenograft Models: Therapeutic Implications

Vincenzo Gianluca Messana, Nicoletta Vitale, Matteo Rovere, Lucia Renzullo, Francesca Arruga, Tiziana Vaisitti, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 250.

DOI: https://doi.org/10.1182/blood-2021-150238

Published: 2021

Journal Articles

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Supriya Chakraborty, Claudio Martines, Fabiola Porro, Ilaria Fortunati, Alice Bonato, Marija Dimishkovska, Silvano Piazza, Brijesh S. Yadav, Idanna Innocenti, Rosa Fazio, Tiziana Vaisitti, Silvia Deaglio, Alberto Zamò, Aleksandar J. Dimovski, Luca Laurenti, Dimitar G. Efremov

Blood (2021) 138 (12): 1053–1066.

DOI: https://doi.org/10.1182/blood.2020008276

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

DOI: https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

DOI: https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome

Supriya Chakraborty, PhD, Claudio Martines, MS, Fabiola Porro, MS, Ilaria Fortunati, BS, Alice Bonato, BA, Marija Dimishkovska, PhD, Brijesh Yadav, PhD, Idanna Innocenti, MDPhD, Rosa Fazio, BA, Tizianna Vaisitti, PhD, Silvia Deaglio, MD, Alberto Zamò, MD PhD, Aleksandar Dimovski, MD PhD, Luca Laurenti, MD, Dimitar G Efremov, MDPhD

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-136668

Published: 2020

Journal Articles

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Francesca Arruga, PhD, Giulia Guerra, Denis Baev, PhD, Catherine Hoofd, PhD, Marta Coscia, MD PhD, Giovanni Francesco D'Arena, MD, Gianluca Gaidano, MD PhD, Richard R. Furman, MD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 5454.

DOI: https://doi.org/10.1182/blood-2019-128308

Published: 2019

Journal Articles

CD79b Expression in Richter's Transformation

John N. Allan, MD, Erica B Bhavsar, BS, Tiziana Vaisitti, PhD, Vincent Sarno, Yifang Liu, Francesca Arruga, PhD, Maureen Joyce, Mathias Schulz, MD MBA, Silvia Deaglio, MD PhD, Richard R. Furman, MD, Amy Chadburn, MD

Blood (2019) 134 (Supplement_1): 4279.

DOI: https://doi.org/10.1182/blood-2019-128305

Published: 2019

Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD

Blood (2019) 134 (Supplement_1): 2862.

DOI: https://doi.org/10.1182/blood-2019-125754

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

DOI: https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

Elisa Bergaggio, Chiara Riganti, Giulia Garaffo, Nicoletta Vitale, Elisabetta Mereu, Cecilia Bandini, Elisa Pellegrino, Verdiana Pullano, Paola Omedè, Katia Todoerti, Luciano Cascione, Valentina Audrito, Anna Riccio, Antonio Rossi, Francesco Bertoni, Silvia Deaglio, Antonino Neri, Antonio Palumbo, Roberto Piva

Blood (2019) 133 (2): 156–167.

DOI: https://doi.org/10.1182/blood-2018-05-850826

Published: 2019

Includes: Supplemental data

Journal Articles

NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia

Francesca Arruga, PhD, Valeria Bracciamà, Alison Yeomans, PhD, Annalisa D'Avola, PhD, Marta Coscia, MD, Giovanni Francesco D'Arena, MD, Gianluca Gaidano, MD PhD, John N. Allan, MD, Richard R. Furman, MD, Graham Packham, PhD, Silvia Deaglio, MD PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2018) 132 (Supplement 1): 1832.

DOI: https://doi.org/10.1182/blood-2018-99-118064

Published: 2018

Journal Articles

Targeting the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities

Andrea Papait, PhD, Tiziana Vaisitti, PhD, Sara Serra, PhD, Valentina Audrito, PhD, Francesco Tito, Giulia Guerra, Dimitar G Efremov, MDPhD, Silvia Deaglio, MD PhD

Blood (2018) 132 (Supplement 1): 240.

DOI: https://doi.org/10.1182/blood-2018-99-118057

Published: 2018

Journal Articles

Hyper-Activation of the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Therapeutic Opportunities

Tiziana Vaisitti, PhD, Sara Serra, PhD, Cinzia Bologna, PhD, Nicoletta Vitale, PhD, Stefania Gobessi, PhD BS, Dimitar G Efremov, MD PhD, Silvia Deaglio, MD

Blood (2017) 130 (Supplement 1): 1721.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1721.1721

Published: 2017

Journal Articles

Genetic and Molecular Characterization of Novel Richter Syndrome Patient-Derived Xenograft Models

Tiziana Vaisitti, PhD, John N. Allan, MD, Esteban Braggio, PhD, Francesca Arruga, PhD, Amy Chadburn, MD, Richard R. Furman, MD, Silvia Deaglio, MD

Blood (2017) 130 (Supplement 1): 4297.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4297.4297

Published: 2017

Journal Articles

Targeting Cellular Metabolism and Survival in Chronic Lymphocytic Leukemia and Richter Syndrome Cells By a Novel NF-Kb Inhibitor

Tiziana Vaisitti, PhD, Federica Gaudino, Samedy Ouk, Sara Serra, PhD, Johannes L. Zakrzewski, MD, Erica B. Bhavsar, John N. Allan, MD, Hsiou-Chi Liou, PhD, Richard R. Furman, Silvia Deaglio, MD PhD

Blood (2016) 128 (22): 304.

DOI: https://doi.org/10.1182/blood.V128.22.304.304

Published: 2016

2 3 4

NARROW

Glutamine and CLL: ready for prime time?

Anti-CD37 alpha-amanitin conjugated antibodies as potential therapeutic weapons for Richter's Syndrome

A new taxonomy for splenic marginal zone lymphoma

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome

Evidence of a Synergistic Cross-Talk between the B Cell Receptor (BCR) and Nicotinamide Phosphoribosyl Transferase (NAMPT) in Richter's Syndrome Patient-Derived Xenograft Models: Therapeutic Implications

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

CD79b Expression in Richter's Transformation

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia

Targeting the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities

Hyper-Activation of the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Therapeutic Opportunities

Genetic and Molecular Characterization of Novel Richter Syndrome Patient-Derived Xenograft Models

Targeting Cellular Metabolism and Survival in Chronic Lymphocytic Leukemia and Richter Syndrome Cells By a Novel NF-Kb Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only